Pacmilimab is under clinical development by CytomX Therapeutics and currently in Phase II for Salivary Gland Cancer. According to GlobalData, Phase II drugs for Salivary Gland Cancer have a 14% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pacmilimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pacmilimab overview
CX-072 is under development for the treatment of solid tumors including lymphomas, non-small cell lung cancer, bladder cancer, triple negative breast cancer, gastric, gastroesophageal junction (GEJ) tumors, esophageal cancer, castration-resistant prostate cancer, esophageal carcinoma, cervix carcinoma, pancreatic carcinoma, ovarian Cancer, mycosis fungoides uterine carcinoma, rectal carcinoma, cervical cancer and testicular cancer, undifferentiated pleiomorphic sarcoma, thymic epithelial cancer, anal squamous cell cancer (SCC), cutaneous squamous cell cancer (cSCC), Merkel cell tumor, small bowel carcinoma and cancers with high tumor mutational burden. It is administered through intravenous route. The monoclonal antibody acts by targeting programmed cell death ligand-1 (PDL-1). The drug candidate is developed based on Probody platform. Probodies are fully recombinant masked antibodies that remain inert in healthy tissue but are activated specifically in the disease microenvironment. It was also under development for metastatic melanoma, metastatic HR-positive/HER2-negative breast cancer, colon adenocarcinoma, sarcoma, peritoneal cancer.
CytomX Therapeutics overview
CytomX Therapeutics (Cytomx) is a clinical-stage biopharmaceutical company. It develops novel therapeutic antibodies and Probody therapeutics for the treatment of cancer. The company’s product pipeline include CX-2029, CX-904 and BMS-986288. Its pipeline carries out SqNSCLC, esophageal/GEJ and solid tumors. Cytomx provides probody therapeutics for the treatment of cancer. The company also carries out various phases of clinical trails. Cytomx is headquartered in South San Francisco, California, the US.
For a complete picture of Pacmilimab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
